What is the key clinical achievement reported for Moderna's mRNA cancer vaccine?

In a first for the nascent cancer vaccine space, Moderna's personalized messenger RNA (mRNA) cancer vaccine slowed the return and spread of melanoma when used alongside Merck & Co.’s checkpoint inhibitor Keytruda in a late-stage clinical trial.

Which companies developed and announced the successful trial results, and what is the current status of data disclosure?

Moderna and Merck & Co. jointly developed and announced the results in a press release; however, they have not yet released detailed data, though they plan to present them at an upcoming medical conference.

In a First, an mRNA Cancer Vaccine Succeeds in Late-Stage Clinical Trial

Aug 19, 2026

Moderna and Merck announced that a personalized mRNA vaccine combined with Keytruda successfully slowed melanoma recurrence in late-stage trials. Detailed data will be presented at an upcoming medical conference.

cen

2026-05-18

Regeneron drops after skin cancer treatment misses late-stage trial goal

2026-08-19

In a First, an mRNA Cancer Vaccine Succeeds in Late-Stage Clinical Trial

2026-08-19

Wall St Futures Flat After Tech Rout; Iran Tensions, Retail Earnings in Focus

2026-08-20

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

In a First, an mRNA Cancer Vaccine Succeeds in Late-Stage Clinical Trial

FAQ